Echocardiography in newly diagnosed atrial fibrillation patients: a systematic review and economic evaluation

EL Simpson,* MD Stevenson, A Scope, E Poku, J Minton and P Evans

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

*Corresponding author

Scientific summary

Echocardiography in newly diagnosed atrial fibrillation patients
Health Technology Assessment 2013; Vol. 17: No. 36
DOI: 10.3310/hta17360

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. AF may be asymptomatic, but may cause palpitations, chest pain, shortness of breath or fainting. If left untreated, AF is a significant risk factor for stroke and other morbidities.

Transthoracic echocardiography (TTE) allows imaging of the heart and blood flow. Echocardiography enables the diagnosis of cardiac abnormalities earlier than would be possible if symptoms were left to develop. Currently, only selected patients with AF are recommended for TTE: those who have clinically suspected heart disease or for whom further information is needed for treatment planning.

Objectives

The assessment investigated the clinical effectiveness and cost-effectiveness of performing routine TTE in all newly diagnosed patients with AF, in comparison with the current practice of selective testing.

Methods

Literature reviews were conducted on the diagnostic accuracy of TTE for clinically important pathologies in AF and their prevalence in patients with AF. A search of MEDLINE, and, for the prevalence review, of 11 other databases was conducted from March to August 2010, and reference lists of relevant articles were checked. For the diagnostic review, the intervention was conventional TTE, and the outcomes sensitivity or specificity. Results were tabulated and discussed in a narrative synthesis.

A mathematical model was constructed to assess the cost-effectiveness of TTE in patients with newly diagnosed AF. It was assumed that TTE would be of benefit only when patient management was changed. It was assumed that if a left atrial abnormality was detected then the patient was at a higher risk of stroke and should receive treatment. The estimated sensitivity and specificity of TTE in identifying left atrial abnormality was incorporated in the model.

A total of 14 separate paired comparisons, comparing a baseline strategy of not using TTE with a comparator strategy that did, were produced. These considered higher- and lower-risk groups, two different age groups, three different types of oral anticoagulant, and both males and females separately.

A simplified approach was also undertaken that evaluated the additional quality-adjusted life-years (QALYs) required in order for TTE to be perceived as cost-effective at a threshold of £20,000 per QALY.

Results

The literature reviews identified 44 diagnostic accuracy studies, five prognostic studies and 16 prevalence studies. Diagnostic accuracy showed high specificities for all selected pathologies, with the majority having specificity of 0.8 or higher, meaning a low proportion of false-positives. Specificity was lower for aortic dissection and pulmonary disease than for other pathologies. For most pathologies there was also quite high sensitivity, with the majority having sensitivity of ≥0.6, with the exceptions of atrial thrombi, atrial
septal defect and pulmonary embolism (PE), for which sensitivity was lower. Prognostic studies indicated that TTE-diagnosed left ventricular (LV) dysfunction or increased left atrial diameter (LAD) was associated with significantly increased risks of thromboembolism or mortality. LV dysfunction also had a significantly increased risk of stroke, and valvular abnormality a significantly increased risk of mortality. Not all studies found a significant association between TTE-diagnosed mitral regurgitation (MR) and prognosis; however, there were reported a significantly increased risk of thromboembolism with mild MR, in contrast with a significantly protective effect of severe MR against stroke. Mitral annular calcification and mitral valve prolapse were not found to be associated with thromboembolism and stroke, respectively. There was a high prevalence (around 25–30%) of ischaemic heart disease, valvular heart disease and heart failure in patients with AF in the included prevalence studies.

The results of the mathematical model indicated that it may be cost-effective to use TTE to make the decision about whether to prescribe warfarin to patients with a CHADS\(_2\) (cardiac failure, hypertension, age, diabetes, stroke doubled) score of 1, or whether to prescribe rivaroxaban to patients aged ≥65 years with a CHADS\(_2\) score of 0.

In the simplified approach, a threshold of 0.0033 was required for a TTE to be cost-effective. This is a very small value, and if a clinician believes there will be some patient gain in addition to providing treatment to reduce stroke risk then TTE is likely to be cost-effective.

**Discussion**

Diagnostic accuracy of TTE and prevalence of pathologies in patients with AF indicate that routine TTE following AF diagnosis would identify pathologies in many patients, particularly with regard to valvular heart disease, ischaemic heart disease and heart failure. TTE seems to be a sufficient diagnostic tool for screening most pathologies included in this review. For completeness of screening, extra testing for PE by lung scan and for atrial thrombi and atrial septal hypertrophy by transoesophageal echocardiography would reduce risk of false-negatives from TTE. However, it is unclear whether identifying these pathologies, in addition to the many diagnosed by TTE, would lead to improvement above that of TTE screening.

It is clear that TTE has the potential to be cost-effective, and this has been indicated in the analyses that assume that the CHADS\(_2\) tool is used. The simplified approach indicates that very few QALYs are required for TTE to be perceived as cost-effective. The modelling undertaken focuses purely on the risks of stroke and of bleed events; if patients will benefit from TTE in other respects it is likely that this diagnostic test would be cost-effective.

**Conclusions**

Transthoracic echocardiography is a non-invasive procedure with the potential to accurately identify treatable pathologies in patients with AF.

Where the CHADS\(_2\) tool is used, the addition of TTE in identifying patients with left atrial abnormality appears to be cost-effective for informing some oral anticoagulation decisions. A simple analysis indicates that the QALYs required for TTE to be cost-effective is small, and that if benefits beyond those associated with a reduction in stroke (at the expense of greater number of bleed) are believed probable then TTE is likely to be cost-effective in all scenarios.

Our findings suggest that further research is needed to follow-up newly diagnosed patients with AF who have undergone TTE, to study treatments given as a result of TTE diagnoses and subsequent cardiovascular events, which could identify additional benefits of routine testing, beyond stroke prevention. Studies
assessing the proportion of people with a CHADS\textsubscript{2} scores of 0 or 1 that have left atrial abnormality would provide better estimates of the cost-effectiveness of TTE, and allow more accurate estimates of the sensitivity and specificity of TTE for identifying left atrial abnormality in AF to be obtained.

**Study registration**

This study is registered as PROSPERO CRD42011001354.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

**Publication**

Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)

Five-year impact factor: 5.804

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is assessed for inclusion in the Database of Abstracts of Reviews of Effects.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: www.hta.ac.uk/

This report
The research reported in this issue of the journal was funded by the HTA programme as project number 08/45/01. The contractual start date was in November 2009. The draft report began editorial review in February 2012 and was accepted for publication in September 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2013. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Health Sciences, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Tom Marshall  Reader in Primary Care, School of Health and Population Sciences, University of Birmingham, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Honorary Professor, Business School, Winchester University and Medical School, University of Warwick, UK

Professor Jane Norman  Professor of Maternal and Fetal Health, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, NICE, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professorial Research Associate, University College London, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk